Sphingomonas spp.
Sphingomonas spp. are aerobic, non-fermenting, Gram-negative rod-shaped bacteria belonging to the Sphingomonadaceae family [1]. The genus comprises at least 95 species, including S. paucimobilis, S. mucosissima, S. echinoides, S. trueperi, S. adhaesiva and S. leidyi [1][2].
Of the large number of Sphingomonas bacteria, two species have been classified as pathogenic to humans: S. paucimobilis and S. mucosissima [2][3]. S. paucimobilis, in particular, is associated with a variety of community-acquired or nosocomial infections. Infections often affect immunosuppressed patients. For example, outbreaks S. paucimobilis have occurred among patients in hematology and oncology wards [2]. In one patient with sickle cell anemia, S. mucosissima caused bacteremia [3].
The following are just some of the many diseases caused by S. paucimobilis and S. mucosissima [2][3]:
Bacteremia
Peritonitis
Meningitis
Soft tissue infections
Urinary tract infections
Visceral abscesses
Endocarditis
Sphingomonas spp. are environmental bacteria that mainly occur in water and in soil. The pathogen was often also found in water sources and on objects in hospitals, including shower heads, oxygen flow meters, and hemodialysis machines [2][3][4][5].
Relevance of pathogen in transmission in endoscopy
Gastroenterology: Low
Pulmonology: Low
Ear, nose, and throat: Low
Urology: Low
Relevance for endoscope surveillance
High concern organism
Transmission route
Transmission can occur via direct or indirect contact with contaminated objects. According to the literature, the most common route of transmission is nosocomial. Contaminated catheters, temperature gages on ventilators, injected drugs, and the hands of medical professionals were identified as sources [2][5][6].
S. paucimobilis were also found during hygienic-microbiological inspections of ultrasound gastroscopes [7].
Resistance to antibiotics
S. paucimobilis are resistant to first-generation penicillins and cephalosporins. S. paucimobilis are sensitive to aminoglycosides, carbapenems and combinations of trimethoprim and sulfamethoxazole (TMP/SMX). Depending on the resistance pattern, third-generation cephalosporins as well as fluoroquinolones can be considered for treatment [2].
Sources and further readings
Bennett JE, Dolin R, Blaser MJ: Mandell, Douglas, and Bennett´s Principles and Practice of Infectious Diseases. Eighth Edition, Elsevier. 2014, Volume 2, Pages 2667-2683.e4.[JRB1].
Assi F et al. Sphingomonas paucimobilis native valve endocarditis and mycotic cerebral aneurysm in a patient with Crohn’s disease: Case report and review of literature. 2023 IDCases 31: e01687.
Angelakis E, Roux V, Raoult D. Sphingomonas mucosissima Bacteremia in patient with sickle cell disease. Emerg Infect Dis. 2009 Jan; 15 (1):133-4.
Maragakis LL et al.: Sphingomonas paucimobilis bloodstream infections associated with contaminated intravenous fentanyl. Emerg Infect Dis. 2009 Jan; 15 (1):12-8.
Lemaitre D et al.: Tracheal colonization with Sphingomonas paucimobilis in mechanically ventilated neonates due to contaminated ventilator temperature probes. J Hosp Infect. 1996, 32 (3):199-206.
Bavaro DF et al.: Sphingomonas paucimobilis outbreak in a dialysis room: Case report and literature review of an emerging healthcare associated infection. American Journal of Infection Control. 2020, 48 (10): 1267-1269.
Christopher G et al.: Risk of infection transmission in curvilinear array echoendoscopes: results of a prospective reprocessing and culture registry. Gastrointest Endosc. 2017, 85 (2):390-397.